Influence of Myxobacteria Metabolites NX52 and NX83 on Colorectal Carcinoma Cell Proliferation_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YANLi-kun ¹ , ZHANGXin ² , ZHANGXun ² , WANGJun ³ , WANYi ³ , SUChun ³ , YAOJian-feng ¹ , MAOZhi-jun ¹

1. Department of General Surgery, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi Province, China;
2. Yan'an University, Yan'an 716000, Shaanxi Province, China;
3. Institute of Microbiology of Shaanxi Province, Xi'an 710043, Shaanxi Province, China;

Corresponding author：

YANLi-kun, Email: yanlikun@sohu.com

Keywords：

Myxobacteria; Metabolite; Colorectal carcinoma cell; Apoptosis

DOI：

10.7507/1007-9424.20150146

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the influence of myxobacteria metabolites NX52 and NX83 on the proliferation of colorectal carcinoma cells and investigate its probable mechanism. Methods The human colorectal carcinoma cell lines HT-29, SW480, and SW1463 were respectively treated with the two metabolites (NX52 and NX83) at different concentrations (0.1 mg/mL, 1.0 mg/mL, and 10.0 mg/mL), the cells of negative control were treated without metabolite. The proliferation inhibition was examined by methyl tthiazolyl tetrazolium assay. The cell morphology character was compared by inverted microscope, and the apoptosis of cell was analyzed by flow cytometry. Results Two kinds of metabolites NX52 and NX83 had time-dose inhibitory effects on proliferation of human colorectal carcinoma cells HT-29, SW480, and SW1463 (P < 0.05). The metabolite NX83 had more obvious proliferation inhibition in the colorectal carcinoma cells as compared with the metabolite NX52 (P < 0.05). After 48 h, the apoptosis rate of the metabolite NX83 for SW1463 cell was observably increased as compared with the negative control group (P < 0.01). Conclusions The two kinds of metabolites NX52 and NX83 from myxobacteria could kill colorectal carcinoma cells in vitro. The possible mechanism might be induced by apoptosis of tumor cells.

Citation： YANLi-kun, ZHANGXin, ZHANGXun, WANGJun, WANYi, SUChun, YAOJian-feng, MAOZhi-jun. Influence of Myxobacteria Metabolites NX52 and NX83 on Colorectal Carcinoma Cell Proliferation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(5): 549-554. doi: 10.7507/1007-9424.20150146 Copy

1.	Gellad ZF, Provenzale D. Colorectal cancer:National and international perspective on the burden of disease and public health impact. Gastroenterology, 2010, 138(6):2177-2190.
2.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
3.	郁宝铭.大肠癌治疗的进展.中国普外基础与临床杂志, 2003, 10(2):89-91.
4.	Nanda K, Bastian LA, Hasselblad V, et al. Hormone replacement therapy and the risk of colorectal cancer:A meta-analysis. Obstet Gynecol, 1999, 93(5 Pt 2):880-888.
5.	Serra AT, Poejo J, Matias AA, et al. Evaluation of opuntia spp. products as antiproliferative agents in human colon cancer cell line (HT29). Food Res Int, 2013, 54(2):892-901.
6.	Dworkin M. Recent advances in the social and developmental biology of the myxobacteria. Microbiol Rev, 1996, 60(1):70-102.
7.	Reichenbach H. Myxobacteria, producers of novel bioactive substances. J Ind Microbiol Biotechnol, 2001, 27(3):149-156.
8.	Wenzel SC, Müller R. Myxobacteria-'microbial factories' for the production of bioactive secondary metabolites. Mol Biosyst, 2009, 5(6):567-574.
9.	Kaiser D, Dworkin M. The myxococcalesⅡ. Washington DC:American Socienty for Microbiology, 1993:257-283.
10.	de Wit M, Kant H, Piersma SR, et al. Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. J Proteomics, 2014, 99:26-39.
11.	Tan KY, Liu CB, Chen AH, et al. The role of traditional Chinese medicine in colorectal cancer treatment. Tech Coloproctol, 2008, 12(1):1-6.
12.	van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy:A systematic review. Am J Gastroenterol, 2006, 101(2):343-350.
13.	Shimkets LJ. Social and developmental biology of the myxobacteria. Microbiol Rev, 1990, 54(4):473-501.
14.	Shimkets L, Dworkin M, Reichenbach H. The myxobacteria//Dworkin M. The prokaryotes. 3rd ed. Berlin:Springer, 2006:31-115.
15.	Wenzel SC, Mueller R. Myxobacterial natural product assembly lines:fascinating examples of curious biochemistry. Nat Prod Rep, 2007, 24(6):1211-1224.
16.	Alberto M. A history of photography with the light microscope. Nuncius, 2012, 27(1):222-223.
17.	Shida H. Role of nucleocytoplasmic RNA transport during the life cycle of retroviruses. Front Microbiol, 2012, 3:179.
18.	Perez-Vilaro G, Jungfleisch J, Saludes V, et al. Host factors in viral life cycles. Math Model Nat Phenom, 2012, 7(5):123-132.
19.	Weissman KJ, Mueller R. Myxobacterial secondary metabolites:bioactivities and modes-of-action. Nat Prod Rep, 2010, 27(9):1276-1295.
20.	Service RF. Tumor-killer made; how does it work? Science, 1996, 274(5295):2009.
21.	Diez J, Martinez JP, Mestres J, et al. Myxobacteria:natural pharmaceutical factories. Microb Cell Fact, 2012, 11:52.
22.	Iizuka T, Jojima Y, Fudou R, et al. Plesiocystis pacifica gen. nov., sp. nov., a marine myxobacterium that contains dihydrogenated menaquinone, isolated from the Pacific coasts of Japan. Int J Syst Evol Microbiol, 2003, 53(Pt 1):189-195.
23.	王军, 闫立昆, 李宏铎, 等.一株黏细菌Archangium gephyra的鉴定及其代谢产物抑菌活性的研究.西北大学学报:自然科学版, 2013, 43(3):437-441.
24.	王军, 王琰, 闫立昆, 等.黏细菌活性代谢产物的互动筛选.西北农林科技大学学报:自然科学版, 2013, 41(11):196-200.

1. Gellad ZF, Provenzale D. Colorectal cancer:National and international perspective on the burden of disease and public health impact. Gastroenterology, 2010, 138(6):2177-2190.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
3. 郁宝铭.大肠癌治疗的进展.中国普外基础与临床杂志, 2003, 10(2):89-91.
4. Nanda K, Bastian LA, Hasselblad V, et al. Hormone replacement therapy and the risk of colorectal cancer:A meta-analysis. Obstet Gynecol, 1999, 93(5 Pt 2):880-888.
5. Serra AT, Poejo J, Matias AA, et al. Evaluation of opuntia spp. products as antiproliferative agents in human colon cancer cell line (HT29). Food Res Int, 2013, 54(2):892-901.
6. Dworkin M. Recent advances in the social and developmental biology of the myxobacteria. Microbiol Rev, 1996, 60(1):70-102.
7. Reichenbach H. Myxobacteria, producers of novel bioactive substances. J Ind Microbiol Biotechnol, 2001, 27(3):149-156.
8. Wenzel SC, Müller R. Myxobacteria-'microbial factories' for the production of bioactive secondary metabolites. Mol Biosyst, 2009, 5(6):567-574.
9. Kaiser D, Dworkin M. The myxococcalesⅡ. Washington DC:American Socienty for Microbiology, 1993:257-283.
10. de Wit M, Kant H, Piersma SR, et al. Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. J Proteomics, 2014, 99:26-39.
11. Tan KY, Liu CB, Chen AH, et al. The role of traditional Chinese medicine in colorectal cancer treatment. Tech Coloproctol, 2008, 12(1):1-6.
12. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy:A systematic review. Am J Gastroenterol, 2006, 101(2):343-350.
13. Shimkets LJ. Social and developmental biology of the myxobacteria. Microbiol Rev, 1990, 54(4):473-501.
14. Shimkets L, Dworkin M, Reichenbach H. The myxobacteria//Dworkin M. The prokaryotes. 3rd ed. Berlin:Springer, 2006:31-115.
15. Wenzel SC, Mueller R. Myxobacterial natural product assembly lines:fascinating examples of curious biochemistry. Nat Prod Rep, 2007, 24(6):1211-1224.
16. Alberto M. A history of photography with the light microscope. Nuncius, 2012, 27(1):222-223.
17. Shida H. Role of nucleocytoplasmic RNA transport during the life cycle of retroviruses. Front Microbiol, 2012, 3:179.
18. Perez-Vilaro G, Jungfleisch J, Saludes V, et al. Host factors in viral life cycles. Math Model Nat Phenom, 2012, 7(5):123-132.
19. Weissman KJ, Mueller R. Myxobacterial secondary metabolites:bioactivities and modes-of-action. Nat Prod Rep, 2010, 27(9):1276-1295.
20. Service RF. Tumor-killer made; how does it work? Science, 1996, 274(5295):2009.
21. Diez J, Martinez JP, Mestres J, et al. Myxobacteria:natural pharmaceutical factories. Microb Cell Fact, 2012, 11:52.
22. Iizuka T, Jojima Y, Fudou R, et al. Plesiocystis pacifica gen. nov., sp. nov., a marine myxobacterium that contains dihydrogenated menaquinone, isolated from the Pacific coasts of Japan. Int J Syst Evol Microbiol, 2003, 53(Pt 1):189-195.
23. 王军, 闫立昆, 李宏铎, 等.一株黏细菌Archangium gephyra的鉴定及其代谢产物抑菌活性的研究.西北大学学报:自然科学版, 2013, 43(3):437-441.
24. 王军, 王琰, 闫立昆, 等.黏细菌活性代谢产物的互动筛选.西北农林科技大学学报:自然科学版, 2013, 41(11):196-200.

Previous Article
Effect of PTEN siRNA on Proliferation and Invasion in Colon Cancer Cells
Next Article
腹腔镜直肠癌根治术62例应用体会

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Influence of Myxobacteria Metabolites NX52 and NX83 on Colorectal Carcinoma Cell Proliferation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content